The Impact of Intravenous Iron Supplementation on Hematinic Parameters and Erythropoietin Requirements in Hemodialysis Patients

Author(s):  
Sepideh Zununi Vahed ◽  
Elham Ahmadian ◽  
Seyedeh Mina Hejazian ◽  
Saba Esmaeili ◽  
Farahnoosh Farnood
PLoS ONE ◽  
2013 ◽  
Vol 8 (11) ◽  
pp. e78930 ◽  
Author(s):  
Abhijit V. Kshirsagar ◽  
Janet K. Freburger ◽  
Alan R. Ellis ◽  
Lily Wang ◽  
Wolfgang C. Winkelmayer ◽  
...  

2019 ◽  
Vol 24 (4) ◽  
pp. 416-422 ◽  
Author(s):  
Alon Bnaya ◽  
Linda Shavit ◽  
Jacek S. Malyszko ◽  
Jolanta Malyszko ◽  
Itzchak Slotki

2016 ◽  
Vol 54 (1) ◽  
pp. 31-36 ◽  
Author(s):  
Naomi Niari Dalimunthe ◽  
Abdurrahim Rasyid Lubis

Introduction. Reticulocyte hemoglobin equivalent (RET-He) is a new parameter for evaluating iron status. This study aims to assess diagnostic value and investigate RET-He as early predictor of response to intravenous iron supplementation. Methods. Seventy-two regular hemodialysis patients at Adam Malik Hospital were studied from April to May 2011. RET-He was compared with conventional iron parameters for identification of iron deficiency. Fifteen patients with iron deficiency anemia were selected to receive 100 mg iron sucrose intravenous during every dialysis session (2x/weeks) for 4 weeks. Results. Receiver operating characteristic (ROC) curve for RET-He revealed the value of area under the curve was 0.818 (p < 0.0001). Using cutoff level 31.65 pg, RET-He showed 81.5% sensitivity and 61.6% specificity. Serum ferritin (r = 0.499, p < 0.0001) and transferrin saturation/ TSAT (r = 0.592, p<0.0001) were correlated to RET-He. Significant improvement in hemoglobin, hematocrit and RET-He were found after intervention (p = 0.023, p = 0.049 and p = 0.019, respectively). Conclusion. RET-He is a useful marker of iron deficiency and early predictor of response to intravenous iron supplementation in regular hemodialysis patients.


2021 ◽  
Vol 12 (2) ◽  
pp. 491-502
Author(s):  
Sarah R. Bloor ◽  
Rudolph Schutte ◽  
Anthony R. Hobson

Iron deficiency anaemia (IDA) is a worldwide healthcare problem affecting approximately 25% of the global population. The most common IDA treatment is oral iron supplementation, which has been associated with gastrointestinal (GI) side effects such as constipation and bloating. These can result in treatment non-adherence and the persistence of IDA. Intravenous iron does not cause GI side effects, which may be due to the lack of exposure to the intestinal lumen. Luminal iron can cause changes to the gut microbiota, aiding the promotion of pathogenic species and decreasing beneficial protective species. Iron is vital for methanogenic archaea, which rely on iron for growth and metabolism. Increased intestinal methane has been associated with slowing of intestinal transit, constipation, and bloating. Here we explore the literature to understand a potential link between iron and methanogenesis as a novel way to understand the mechanism of oral iron supplementation induced GI side effects.


Sign in / Sign up

Export Citation Format

Share Document